Drug Trial Radar · NCT00095654
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Last checked: Nov 20, 2026Latest source record: Nov 10, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,000
Actual
Start
Jul 2001
Primary completion
Not stated
Study completion Oct 2006
Sponsor
- Lead sponsor
- Gerstein, Hertzel, MDIndividual
- Sponsor type
- Individual
- Collaborators
- Canadian Institutes of Health Research (CIHR); Aventis Pharmaceuticals; GlaxoSmithKline; King Pharmaceuticals is now a wholly owned subsidiary of Pfizer; Wyeth is now a wholly owned subsidiary of Pfizer
- First posted
- Nov 8, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if ramipril and/or rosiglitazone prevent the onset of type 2 diabetes.
Conditions
- Impaired Glucose Tolerance
- Cardiovascular Disease
- Glucose Metabolism Disorders
Interventions
RamiprilDrug
RosiglitazoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- diabetes
- death
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.